Cancer Immunity and Metabolic Reprogramming: Pioneering Precision Immunotherapies

Cancer immunotherapy stands as a transformative advancement in oncology, offering new hope through novel treatments that utilize the body’s immune system to fight cancer. However, the success of these therapies is intricately limited by complex interactions between the immune system and tumors. Essential immune cells like cytotoxic T cells (CTLs) play pivotal roles in targeting cancer cells, whereas regulatory T cells (Tregs) and tumor-associated macrophages (TAMs) promote immune suppression, aided by cytokines such as TGF-β, IL-10, and VEGF. Moreover, myeloid-derived suppressor cells (MDSCs) further reduce immune effectiveness through enzymes like arginase. Metabolic changes within the tumor environment, including nutrient depletion and waste product accumulation, also weaken immune responses. Yet, recent technological breakthroughs in single-cell analysis have opened new avenues for understanding and targeting these dynamics.

This Research Topic is dedicated to deepening the understanding and innovation of cancer immunity and immunotherapy. It is focused on deciphering the complex mechanisms of the anti-tumor immune response within the tumor microenvironment, particularly exploring the roles of immune checkpoints and metabolic pathways. The ultimate aim is to uncover synergistic strategies that blend immune modulation and metabolic reprogramming to remodel tumor environments favorably, thereby catalyzing breakthroughs that bridge basic research and clinical application.

Focused on the nexus of immune regulation and metabolic interaction within cancer therapy, this Research Topic invites contributions that unravel how immune cells like CTLs, Tregs, TAMs, and MDSCs orchestrate anti-tumor activity. Key areas of interest include:

- Regulation of immune checkpoints
- Advances in adoptive cell therapies
- Innovations in cancer vaccine development
- Impact of metabolic reprogramming on immune and tumor cells
- Exploration of specific metabolic pathways influencing immune escape and tumor progression

By promoting interdisciplinary research, this initiative aims to integrate preclinical discoveries with clinical advancements, highlighting novel strategies to circumvent therapy resistance and enhance the efficacy of immunotherapies.